Literature DB >> 26030700

Deep brain stimulation for the obsessive-compulsive and Tourette-like symptoms of Kleefstra syndrome.

David J Segar1, Yosef G Chodakiewitz1, Radmehr Torabi1,2, G Rees Cosgrove1,2.   

Abstract

Deep brain stimulation (DBS) has been reported to have beneficial effects in severe, treatment-refractory cases of obsessive-compulsive disorder (OCD) and Tourette syndrome (TS). In this report, the authors present the first case in which DBS was used to treat the neuropsychiatric symptoms of Kleefstra syndrome, a rare genetic disorder characterized by childhood hypotonia, intellectual disability, distinctive facial features, and myriad psychiatric and behavioral disturbances. A 24-year-old female patient with childhood hypotonia, developmental delay, and diagnoses of autism spectrum disorder, OCD, and TS refractory to medical management underwent the placement of bilateral ventral capsule/ventral striatum (VC/VS) DBS leads, with clinical improvement. Medical providers and family observed gradual and progressive improvement in the patient's compulsive behaviors, coprolalia, speech, and social interaction. Symptoms recurred when both DBS electrodes failed because of lead fracture and dislodgement, although the clinical benefits were restored by lead replacement. The symptomatic and functional improvements observed in this case of VC/VS DBS for Kleefstra syndrome suggest a novel indication for DBS worthy of further investigation.

Entities:  

Keywords:  AC = anterior commissure; DBS = deep brain stimulation; EHMT1 protein; GAF = global assessment of functioning; Kleefstra syndrome; OCD = obsessive-compulsive disorder; PC = posterior commissure; TS = Tourette syndrome; VCA/S = ventral capsule/ventral striatum; YBOCS = Yale-Brown Obsessive Compulsive Scale; deep brain stimulation; human; obsessive-compulsive disorder; ventral striatum

Mesh:

Year:  2015        PMID: 26030700     DOI: 10.3171/2015.3.FOCUS1528

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  2 in total

1.  A de novo splice site mutation in EHMT1 resulting in Kleefstra syndrome with pharmacogenomics screening and behavior therapy for regressive behaviors.

Authors:  Amit Kumar Mitra; Jessica Dodge; Jody Van Ness; Israel Sokeye; Brian Van Ness
Journal:  Mol Genet Genomic Med       Date:  2016-12-26       Impact factor: 2.183

2.  An open-label prospective pilot trial of nucleus accumbens deep brain stimulation for children with autism spectrum disorder and severe, refractory self-injurious behavior: study protocol.

Authors:  Han Yan; Lauren Siegel; Sara Breitbart; Carolina Gorodetsky; Alfonso Fasano; Aliya Rahim; Alvin Loh; Abhaya V Kulkarni; George M Ibrahim
Journal:  Pilot Feasibility Stud       Date:  2022-02-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.